Predicting Heart Failure Events in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial

COMMENTED

Type 2 Diabetes

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.1016/S2213-8587(20)30038-3.

COMMENTED

Type 2 Diabetes

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Circulation

Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators.

doi: 10.1161/CIRCULATIONAHA.120.050255

Diabetes - GeneralGlycemic Control

A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative

Metabolism.

Mongraw-Chaffin M, LaCroix AZ, Sears DD, Garcia L, Phillips LS, Salmoirago-Blotcher E, Zaslavsky O, Anderson CA

doi: 10.1016/

Diabetes - GeneralType 2 Diabetes

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetologia.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B

doi: 10.1007/s00125-018-4644-9.

Diabetes - GeneralType 2 Diabetes

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME^® trial

Eur Heart J.

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Erik Johansen O, Inzucchi SE

Diabetes - GeneralType 2 Diabetes

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

J Am Heart Assoc.

Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L

doi: 10.1161/JAHA.116.004743.

COMMENTED

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 3 Recommended and commented by Prof. Dr Isabella Sudano, Faculty Member

doi: 10.1001/jama.2020.1906.

Diabetes - GeneralType 2 Diabetes

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial

Diabetes Care.

Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group

doi: 10.2337/dc17-1091.

RECOMMENDED

Type 2 Diabetes

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus

Eur Heart J.

Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN

doi: 10.1093/eurheartj/

Related content

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME^® trial